Serfontein W J, Mekel R, Bank S, Barbezat G, Novis B
Res Commun Chem Pathol Pharmacol. 1979 Nov;26(2):383-9.
In the course of a double-blind clinical trial of treatment involving a bismuth protein complex (Bicitropeptide), an antacid and placebo, blood samples (33 patients) and urine samples (43 patients) were collected for bismuth analysis from patients on bismuth therapy at the beginning of the trial (week 0) and at weeks 3 and 6. Base line blood (2 - 11 ng/l) and urine (2 - 29 ng/l) values were not zero and appeared to have reached "saturation" values in many cases after 3 weeks (Blood : 4 - 33 ng/l and Urine 60 - 600 ng/l). After 6 weeks, blood values were 5 - 20 ng/l and urine values 63 - 780 ng/l. It is concluded that these blood and urine levels are not associated with significant toxicity in man.
在一项涉及铋蛋白复合物（比西托肽）、抗酸剂和安慰剂的双盲治疗临床试验过程中，在试验开始时（第0周）以及第3周和第6周，从接受铋治疗的患者中采集了血样（33例患者）和尿样（43例患者）用于铋分析。基线血铋（2 - 11纳克/升）和尿铋（2 - 29纳克/升）值不为零，在许多情况下，3周后似乎已达到“饱和”值（血铋：4 - 33纳克/升，尿铋：60 - 600纳克/升）。6周后，血铋值为5 - 20纳克/升，尿铋值为63 - 780纳克/升。得出的结论是，这些血铋和尿铋水平与人体的显著毒性无关。
